

In Silico and In Vitro Studies of 4-Hydroxycoumarin-Based Heterocyclic Enamines as Potential Anti-Tumor Agents

Mediha Assad ^{1,2}, Rizwan Nasir Paracha ³, Abu Bakar Siddique ⁴, Muhammad Ashraf Shaheen ^{4,*}, Nadeem Ahmad ⁵, Muhammad Mustaqeem ⁴, Fariha Kanwal ⁶, Muhammad Zia Ul Mustafa ⁴, Muhammad Fayyaz ur Rehman ⁴, Sumaya Fatima ⁷ and Changrui Lu ^{*}

1 College of Biological Sciences and Medical Engineering, Donghua University, 2999 North Ren Min Road, Shanghai 201620, China

2 Department of Chemistry, Government Graduate Islamia College for Women Cantt Lahore, Lahore 54000, Pakistan

3 Department of Chemistry, Thal University Bhakkar, Bhakkar 30000, Pakistan

4 Institute of Chemistry, University of Sargodha, Sargodha 40100, Pakistan;
abubakar.siddique@uos.edu.pk (A.B.S.)

5 Department of Pharmacy, Comsats University Islamabad, Lahore Campus, Lahore 54000, Pakistan


6 School of Biomedical Engineering, Shanghai Jiaotong University, Shanghai 200030, China

7 Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China


* Correspondence: ashraf.shaheen@uos.edu.pk (M.A.S.); crlu@dhu.edu.cn (C.L.)

Table S1. IC₅₀ values of synthesized compounds (3a-i) by potato disc tumor assay.

Sample	IC ₅₀ (mg/mL) value	Sample	IC ₅₀ (mg/mL) value
3a	5±0.5	3f	27.7±3
3b	37.1±4	3g	1.12±0.2
3c	2.12±0.3	3h	1.70±0.3
3d	22.7±3	3i	29.6±4
3e	2.33±0.2	Vinblastine (Standard)	7.5±0.6




(A)




(B)

Figure S1. (A) ^1H -NMR spectrum of **4a**. (B) ^{13}C -NMR spectrum of **4a**.




(A)



(B)

Figure S2. (A) ^1H -NMR spectrum of **4b**. (B) ^{13}C -NMR spectrum of **4b**.







Figure S3. (A) ¹H-NMR spectrum of **4c**. (B) ¹³C-NMR spectrum of **4c**.



(A)





Figure S4. (A) ^1H -NMR spectrum of **4d**. (B) ^{13}C -NMR spectrum of **4d**.



(A)






Figure S5. (A) ¹H-NMR spectrum of **4e**. (B) ¹³C-NMR spectrum of **4e**.




(A)



(B)

Figure S6. (A) ^1H -NMR spectrum of **4f**. (B) ^{13}C -NMR spectrum of **4f**.







Figure S7. (A) ^1H -NMR spectrum of **4g**. (B) ^{13}C -NMR spectrum of **4g**.



(A)




Figure S8. (A) ^1H -NMR spectrum of **4h**. (B) ^{13}C -NMR spectrum of **4h**.









Figure S9. (A) ^1H -NMR spectrum of **4i**. (B) ^{13}C -NMR spectrum of **4i**.








(4b)




(4c)





(4d)








(4e)




(4f)





(4g)





(4h) Vinblastine



(4i) Native ligand (5XG) of CDK-8




Figure S10. Docking Simulations of Compounds (4a-i, Vinblastine and native ligand) with CDK-8 protein.